Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | AR | P10275 | 4/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822778 | 0.76 | AKR1B1 (0.47) | AKR1B1CYP19A1 | |
| SCHEMBL1825538 | 0.74 | BACE1 (0.38) | AKR1B1CYP19A1ARALOX12ABCB1 | |
| SCHEMBL1821671 | 0.72 | ALOX12 (0.39) | AKR1B1CYP19A1ARSIRT2ALOX12 | |
| SCHEMBL1822169 | 0.70 | AKR1B1 (0.44) | AKR1B1CYP19A1ARALOX12MAOB | |
| SCHEMBL27278870 | 0.68 | AKR1B1 (0.75) | AKR1B1 | |
| SCHEMBL2377152 | 0.68 | AKR1B1 (0.39) | AKR1B1CYP19A1ARALOX12MAOB | |
| SCHEMBL1464135 | 0.68 | BACE1 (0.41) | AKR1B1ARALOX12MAOB | |
| SCHEMBL16136455 | 0.67 | AKR1B1 (0.40) | AKR1B1CYP19A1ARABCB1ABCG2 | |
| SCHEMBL1825156 | 0.66 | AKR1B1 (0.53) | AKR1B1SIRT2 | |
| SCHEMBL1820424 | 0.66 | AKR1B1 (0.43) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | AKR1B1 2656/4885CYP19A1 1456/4885AR 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.